演題詳細

ポスター / Poster

ポスター 8 (Poster 8) :AML:治療成績

print

日程
2013年10月11日(金)
時間
16:50 - 17:50
会場
ポスター会場 / Poster (ロイトン札幌 3F ロイトンホールABCD)
座長・司会
政氏 伸夫 (Nobuo Masauji):1
1:北海道大学大学院保健科学研究院保健科学部門 病態解析学分野
 
前へ戻る

Recent treatment results of elderly (65 years or older) acute leukemia patients

演題番号 : PS-1-56

土橋 史明 (Nobuaki Dobashi):1,2、薄井 紀子 (Noriko Usui):1,2、矢野 真吾 (Shingo Yano):2、矢萩 裕一 (Yuichi Yahagi):2、武井 豊 (Yutaka Takei):1,2、杉山 勝紀 (Katsuki Sugiyama):2、高原 忍 (Shinobu Takahara):2、塩田 祐子 (Yuko Shiota):1,2、南 次郎 (Jiro Minami):1,2、齋藤 健 (Takeshi Saito):2、大場 理恵 (Rie Ohba):1,2、相羽 惠介 (Keisuke Aiba):2

1:Dept. Clin. Oncol. & Hematol. Jikei University Daisan Hospital, Tokyo, Japan、2:Dept. Clin. Oncol. & Hematol. Jikei University School of Medicine, Tokyo, Japan

 

The most appropriate chemotherapies for elderly acute leukemia (AL) patients are still controversial. In order to assess the recent treatment results, we retrospectively analyzed the clinical outcome of elderly (65 years or older) AL patients in our institution. Between January 2008 and December 2012, 37 untreated elderly AL patients [median age: 73 (65-82) years, M/F: 25/12, acute myelogenous leukemia (AML): 27 (therapy-related leukemia: 4, core-binding factor leukemia: 2), acute promyelocytic leukemia (APL): 2, acute lymphoblastic leukemia (ALL): 8 (Philadelphia chromosome positive (Ph+): 4)] were admitted to our institution. Twenty-three patients treated with intensive chemotherapy (IC), 6 (Ph+ ALL and APL) with target therapies (TT), 5 with low-IC, and 3 with best supportive care (BSC) as induction therapy. Twenty-four patients (64.9%) achieved complete remission (CR) [AML: 16 (59.3%), ALL: 7 (87.5%), APL: 1 (50%), IC: 18 (78.3%), TT: 5 (83.3%), low-IC: 1 (20%), BSC: 0]. However, most patients eventually relapsed in a short period of time. The median relapse-free survival (RFS) and overall survival (OS) were 9.7 (AML: 10.3, ALL: 5.3, IC: 9.5, TT; 19.3) and 17.8 (AML: 17.8, ALL: 10.8, IC: 19.9, TT; 10.8, low-IC: 4.0) months, respectively. Regarding induction therapy, IC and TT were useful to selected patients. On the other hand, new post-remission treatments approach is still required in order to resolve poor outcome of RFS and OS.

前へ戻る